Supreme Court Preserves Access to Abortion Pill Mifepristone Amid Ongoing Lawsuit
The US Supreme Court has issued an order preserving women's access to mifepristone, the drug used in the most common method of abortion, while legal challenges continue. The decision rejects lower-court restrictions that would have required in-person doctor visits and halted mail delivery of the medication. This emergency relief allows patients to obtain the drug through pharmacies or via mail without immediate disruption, likely maintaining the status quo until at least next year as the case proceeds through appeals. The ruling grants requests from manufacturers Danco Laboratories and GenBioPro, overturning a Fifth Circuit Court of Appeals decision that favored Louisiana’s lawsuit against FDA regulations. Justices Clarence Thomas and Samuel Alito dissented, arguing the manufacturers are not entitled to protect profits from what they termed illegal activities under the Comstock Act. The case highlights ongoing tensions between anti-abortion groups and the FDA regarding telehealth prescriptions and safety reviews. With medication abortions accounting for nearly two-thirds of all procedures in 2023, this decision significantly impacts reproductive healthcare access across the United States, particularly in states with strict abortion bans.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection